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Weaver syndrome (WS), an overgrowth/intellectual disability syndrome (OGID), is caused by pathogenic variants in the histone meth-
yltransferase EZH2, which encodes a core component of the Polycomb repressive complex-2 (PRC2). Using genome-wide DNA methyl-
ation (DNAm) data for 187 individuals withOGID and 969 control subjects, we show that pathogenic variants in EZH2 generate a highly
specific and sensitive DNAm signature reflecting the phenotype of WS. This signature can be used to distinguish loss-of-function from
gain-of-function missense variants and to detect somatic mosaicism. We also show that the signature can accurately classify sequence
variants in EED and SUZ12, which encode two other core components of PRC2, and predict the presence of pathogenic variants in un-
diagnosed individuals with OGID. The discovery of a functionally relevant signature with utility for diagnostic classification of sequence
variants in EZH2, EED, and SUZ12 supports the emerging paradigm shift for implementation of DNAm signatures into diagnostics and
translational research.Introduction
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of the polycomb repressive complex 2 (PRC2), which regu-
lates genome-wide chromatin structure and gene expres-
sion through methylation of lysine 27 of histone H3; this
mark drives chromatin condensation and transcriptional
repression.4 EZH2 in combination with EED (embryonic
ectoderm development) and SUZ12 (SUZ12 polycomb
repressive complex 2 subunit) form the core complex of
PRC2. Recently, it has been established that pathogenic
variants in EED (MIM: 605984) and SUZ12 (MIM:
606245) cause two clinically overlapping OGID syn-
dromes, Cohen-Gibson (MIM: 617561) and SUZ12-related
overgrowth syndrome, respectively.5,6
The phenotypic consequences of pathogenic variants in
EZH2 are variable; clinical diagnosis is therefore chal-
lenging in the absence of the characteristic facial pheno-
type. The clinical features can be age dependent, and in
the largest case series to date, fewer than half (47%) of in-
dividuals with EZH2 pathogenic variants were considered
to have the classic Weaver syndrome facial gestalt.1 Tall
stature, with a height at least two standard deviations
(SDs) above the mean, is the most consistent EZH2-related
clinical feature, present in 90% of affected individuals.
Intellectual disability is also common, present in 80%,
but can be very mild. However, tall stature and intellectual
disability are nonspecific and generally common, which
limits their utility as discriminating clinical features of
WS and its related disorders.1
Several studies have shown that WS-associated patho-
genic EZH2 variants cause a loss rather than a gain of enzy-
matic activity. Cohen et al.7 found reduced histone meth-
yltransferase activity using an in vitro assay. In a mouse
model of WS, decreased di- and trimethyl-H3K27 were
identified in homozygous and heterozygous embryos,
thereby supporting a role for reduced methyltransferase
function as the cause of WS.8
We and others have recently found that disorders caused
by pathogenic sequence variants in epigenes (genes encod-
ing proteins that demonstrate ‘‘epigenetic’’ functions) may
cause cells to change their typical DNA methylation
(DNAm)and transcriptional profiles. Individualswithpath-
ogenic variants in some epigenes exhibit disorder-specific
signatures comprised of genome-wide, multilocus DNA
methylation alterations. These signatures can be used to
functionally classify sequence variants, with high sensi-
tivity and specificity and to improve our understanding of
the pathophysiology of the associated genetic disor-
der.9–15 We have also shown that pathogenic sequence var-
iants in clinically overlapping, genetically distinct disorders
may lead to similar epigenetic patterns of regulatory disrup-
tion. Our group has recently reported this phenomenon in
Kabuki syndrome (KS) types 1 and 2, for which sequence
variants in different causative genes (KMT2D [MIM:
602113], KDM6A [MIM: 300128]) share an epigenetic dis-
ease signature10 and in BAF complex-associated disorders,
we and others have reported similar findings.12,15
In this study, we identified a genome-wide DNAm signa-
ture associated with pathogenic variants in EZH2. We wereThe Amesuccessful in using this signature to detect somatic mosai-
cism for EZH2 variants and to classify both gain-of-func-
tion (GoF) and loss-of-function (LoF or hypomorphic)
sequence variants in EZH2. Further, this EZH2 signature
can be used to identify and classify pathogenic sequence
variants in other genes in the PRC2 core complex, namely
EED and SUZ12. These data provide evidence for conver-
gent molecular signatures for three PRC2 complex genes
and highlight the functional relevance of this DNAm
signature for predicting variant pathogenicity, detecting
somatic mosaicism, and most importantly, for discrimi-
nating different functional effects of sequence variants.Subjects and Methods
Cohort with EZH2 Variants
The research was approved by the Research Ethics board at The
Hospital for Sick Children (REB# 1000038847) and consent was
obtained from participating subjects and/or their parents or guard-
ians. Peripheral blood samples from subjects with EZH2 variants
(n ¼ 40) were used in this study, of whom eight unrelated subjects
were used as a discovery set with a clinical diagnosis of Weaver
syndrome and pathogenic sequence variants in EZH2, seven previ-
ously published in Gibson et al.2 and Cohen and Gibson7 and one
unpublished case (see Table S1). Another unrelated cohort with
clinical diagnosis of WS consisting of eight previously published
WS individuals with pathogenic EZH2 sequence variant as
part of the Childhood Overgrowth Consortium in the UK1 was
used as an independent validation set (Table S2). This EZH2
variant cohort included a familial case series with a pathogenic
EZH2 sequence variant: GenBank: NM_004456.4; c.466A>G
(p.Lys156Glu). The proband has a family history of overgrowth,
and the EZH2 sequence variant segregated with the overgrowth
phenotype over three generations. The family included the pro-
band, two affected siblings, the mother, and the maternal grandfa-
ther.3 An additional test cohort for EZH2 variant classification con-
sisted of 19 samples with EZH2 variants (see Table S9), collected
from PreventionGenetics, USA; from British Columbia Children’s
Hospital at the University of British Columbia, Vancouver, Can-
ada; from St George’s University Hospitals NHS Foundation Trust,
London, UK; from the Department of Human Genetics, Yoko-
hama City University Graduate School of Medicine, Fukuura,
Japan; from Laboratorio di Genetica Medica, ASST Papa Giovanni
XXIII, Piazza OMS, Bergamo, Italy; from the Department of Med-
ical Genetics, University of Alberta, Edmonton, Canada; and from
the Victorian Clinical Genetics Services, Murdoch Children’s
Research Institute, Royal Children Hospital, Victoria, Australia.Cohort with EED Variants
Three individuals with de novo EED pathogenic variants were pre-
viously reported5–7 and are described in Table S9.Cohort with SUZ12 Variants
Five individuals with SUZ12 variants were recruited to the study
including one previously reported familial case subject comprised
of the proband and affected father.6 Two individuals with
missense variants in SUZ12 recruited from British Columbia Chil-
dren’s Hospital at the University of British Columbia, Vancouver,
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Medicine from the University of Hong Kong. One autism-affected
case subject with 17q11.2 dup overlapping SUZ12 identified at the
Hospital for Sick Children, Toronto, Canada. Full description of
the sequence variants is given in Table S9.
All gene variant annotations as well as in silico prediction using
PolyPhen-2, SIFT, and MutationTaster were generated using
Alamut visual 2.11. CADD scores were obtained using CADD data-
base v.1.4.Control Cohort
Genomic DNA from peripheral bloodwas obtained on a set of con-
trols (n ¼ 23) selected as age- and sex-matched neurotypical con-
trols to the EZH2 discovery set (Table S3). In addition, 148 controls
were used to determine the specificity of the DNAm signature.
These control samples were obtained from the POND Network,
The Hospital for Sick Children, and The University of Michigan
(Dr. Greg Hanna).16 Neurotypical was defined as healthy and
developmentally normal on formal cognitive/behavioral assess-
ments (samples from POND and The University of Michigan) or
via physician/parental screening questionnaires (Hospital for
Sick Children). Additional blood controls were obtained from
publicly available datasets taken from the Gene Expression
Omnibus. In total, we used data from 718 unrelated subjects
from the general population without clinically obvious neurode-
velopmental phenotypes, who hadDNA extracted fromperipheral
blood and had undergone profiling with the Illumina 450k array
(GEO: GSE54670, GSE54399, GSE51245, GSE89353, GSE36064,
GSE128801, GSE53045, GSE40279, GSE42861).17–25 We restricted
subjects to those age <50 years to match our WS cohort and
excluded one control sample, as it presented as outlier based on
principal component analysis (PCA) of autosomal probes. For
detailed information see Table S7 and Figure S5.DNAm Array Processing
Genome-wide DNAm profiling on control and affected subjects
matched for age and sex was performed at The Center for Applied
Genomics (TCAG), SickKids Research Institute, Toronto, ON, Can-
ada. Genomic DNA from each subject was sodium bisulfite con-
verted using the EpiTect Bisulfite Kit (EpiTect PLUSBisulfite Kit,
QIAGEN), according to the manufacturer’s protocol. Modified
genomic DNA was then processed and analyzed on the Infinium
HumanMethylationEPIC BeadChip (Illumina 850K) according to
the manufacturer’s protocol.26 The distribution of the samples
on the arrays was randomized for both disease and control sam-
ples. All signature-derivation samples (WS and controls) were
run in the same batch.
Quality Control and Normalization
The raw IDAT files were converted into b-values, which represent
DNAm levels as a percentage (between 0 and 1), using the minfi
Bioconductor package in R. Data preprocessing included filtering
out non-specific probes (41,135 probes); probes with detection
p value > 0.05 in more than 25% of the samples (824 probes);
probes with single-nucleotide polymorphic sites (SNPs) located
within 10 bp of the targeted CpG site or a single base extension
as well as probes near SNPs with minor allele frequencies above
1% (n ¼ 29,958); probes with raw beta¼ 0 or 1 in> 0.25% of sam-
ples (n ¼ 21); non-CpG probes (n ¼ 2,932); and X and Y chromo-
some probes (n¼ 19,627) for a total of 91,343 probes removed and
a total of n ¼ 774,516 probes remaining for differential methyl-
ation analysis. Standard quality control metrics in minfi were
used, includingmedian intensity QC plots, density plots, and con-598 The American Journal of Human Genetics 106, 596–610, May 7,trol probe plots: all samples passed quality control and were
included in the study.
Differential DNAm Analysis
The analysis was performed using our previously published proto-
col.10 Differential DNAm analysis between WS and controls was
performed at 774,516 CpG sites using beta scores, which represent
DNAm levels as a percentage (between 0 and 1). The b-value from
each sample at the remaining 774,516 CpGs was used for down-
stream analysis and generation of a DNAm signature. Beta values
were logit transformed to M-values using the following equation:
log2(beta/(1-beta)). A linear regression modeling using limma
package27 was used to identify the differentially methylated
probes. We estimated blood cell proportions using Houseman’s al-
gorithm and the Bioconductor packages, minfi and FlowSorted.
Blood.EPIC. This method generates proportions of CD8þ T cells,
CD4þ T, natural killer, B cells, monocytes, and granulocytes
(mainly neutrophils, Neu) (Table S13).28 These estimated values
for each cell component were incorporated into the model matrix
of the regression analysis as covariates along with sex and age. The
analysis was done on the discovery set of 8WS and 23 controls per
the following regression model: DNAm was regressed against
sexþageþCD8TþCD4TþNKþBcellþMonoþNeu for each CpG
site. The generated p values were corrected for multiple testing us-
ing the Benjamini-Hochberg method. A significant difference in
DNAm between WS and control samples for each CpG site was
required to meet the cutoffs of Benjamini-Hochberg adjusted p
values < 0.05 and |Db| R 0.10 (10% methylation differences) as
previously reported.9,10
Generation of Disease Score Classification Model using
Correlation Analysis
We used a previously described pipeline for generating disease
scores using an established disease-specific DNAm signature.9,10
At each of the 229 signature CpGs, a median DNAm level was
computed across the WS individuals (n ¼ 8) used to generate the
signature, resulting in a reference profile. Similarly, a robust me-
dian-DNAm reference profile for the signature controls (n ¼ 23)
was created. The classification of each additional gene variant or
control DNAm sample was based on extracting a vector BRsigR of
its DNAm values in the signature CpGs and comparing BRsigR to
the two reference profiles computed above. EZH2 score was
defined as: EZH2 score ¼ r(BRsigR, WS profile) – r(BRsigR, control pro-
file)) where r is the Pearson correlation coefficient. A classification
model was developed based on scoring each new DNAm sample
using the EZH2 Score: a test sample with a positive score is more
similar to the WS reference profile based on the signature CpGs
and is therefore classified as ‘‘pathogenic’’ whereas a sample with
a negative score is more similar to the control-blood reference pro-
file and is classified as ‘‘benign.’’ The classification is implemented
in R. To test specificity, EPIC array data from 148 additional neuro-
typical controls were scored and classified. To test sensitivity, eight
additional unrelated WS individuals with EZH2 pathogenic vari-
ants were scored and classified.
Generation of Machine Learning Model for Variant
Classification
Using the R package caret, probes with very similar methylation
patterns with correlation greater or equal to 90% (redundant
probes) were removed as we previously described10 leading to a
subset of 119 CpGs. Next, we developed a machine-learning2020
model, a support vector machine (SVM) model with linear kernel
that had been trained on the significant CpG sites from the discov-
ery cohorts after further filtering to remove redundant CpGs. The
model was set to the ‘‘probability’’ mode to generate SVM scores
ranging between 0 and 1 (or 0% and 100%), thus classifying sam-
ples as ‘‘WS’’ (high scores) or ‘‘not-WS’’ (low scores). This SVM
model was built as a tool for the classification of variants in
EZH2, EED, and SUZ12.Identification of Differentially Methylated Regions
To identify differentially methylated regions (DMRs) that are asso-
ciated with EZH2 variants, we used the bumphunting method29
which strengthens the detection of regional differences by
combining differential-methylation patterns across neighboring
CpG sites.30 The bumphunting design matrix accounted for the
potential confounding effects of sex and age and was used to iden-
tify regions with consecutive CpGs nomore than 0.5 Kb apart and
an average regional methylation difference |Db|R 10%. Statistical
significance was established using 1,000 randomized bootstrap it-
erations, as is recommended in the Bioconductor bumphunter
package when accounting for confounders. The resulting DMRs
were post-filtered to retain only those with p value < 0.05 and a
length (number of consecutive CpGs) of at least five CpGs. The
analysis was performed on the same sets of case and control sub-
jects used as the discovery cohort.Genomic and Gene-Set Enrichment Analyses
For genomic enrichment analysis, the list of 229 CpG sites (fore-
ground genomic regions) was submitted to GREAT (Genomic Re-
gions Enrichment of Annotations Tool)31 using the default set-
tings. We used the set of CpG sites after minfi probe quality
control (n ¼ 774,516) as the background genomic regions.
Gene-set enrichment analysis was performed using g: Profiler to
identify Gene Ontology (GO) Biological Process terms overrepre-
sented in the annotations of genes overlapping the differentially
methylated CpGs. The enriched GO terms with Benjamini-Hoch-
berg corrected p values < 0.05 were reported. The redundant GO
terms were reduced and visualized as interactive networks using
EnrichmentMap app on the Cytoscape platform as previously
described.32Enzymatic Activity of EZH2
The luminescence assay to determine EZH2 enzymatic activity for
the p.Ala738Thr sequence variant was performed at BPS Biosci-
ence as follows: a 50 ml reactionmix containing 50 mM S-adenosyl-
methionine, EZH2 enzyme (as part of an artificially assembled
PRC2 complex derived from baculovirus expression vectors), and
20 mM phosphate buffer (pH 7.4), 0.05% Tween-20 HMT buffer
2 (BPS #52170) was added to wells coated with the substrate. Incu-
bation was done for 1 h at room temperature, then antibody
against methylated lysine 27 (K27) residue of histone H3 was
added and incubated for 1 h. Secondary horseradish peroxidase
(HRP)-labeled antibody was added and incubated for 30 min.
Finally, HRP chemiluminescent substrates were added and lumi-
nescence was read in using a microplate chemiluminescence
reader. Control replicates were done with two different lot
numbers of baculovirus-expressed human EZH2 bearing the ca-
nonical protein sequence, and a third iteration of the assay was
done with EZH2 bearing a threonine residue at position 738, re-
placing the alanine.The AmeMolecular Protein Modeling
We applied PRODRG,33 a tool for high-throughput crystallog-
raphy of protein-ligand complexes, to build ad hoc topologies of
S-Adenosyl methionine (SAM) and S-Adenosyl homocysteine res-
idues for Gromacs. We performed homology modeling via
Modeler v.9.22,34 setting the MD refinement value to ‘‘refine.ver-
y_slow’’ and leaving the remaining parameters at default. Only
the SET and post-SET domains of EZH2 were modeled to conform
with (1) the absence of known structures for the post-SET domain
and (2) the need to simplify the model also in terms of computa-
tional costs and complexity. As a template structure for the
modeling of SET domain we used 4MI0.35
Energy Minimization and DG Measurements
Potential energy minimization was performed on each EZH/SAH
complex structures with GROMACS 2019 through a multi-step
conjugate gradient algorithm using Amber99-ILDN force-field.36
The minimization procedure automatically stopped when the re-
sulting structure reached an RMSD threshold of 0.01. Estimates
of the Free Energy of binding of each complex was measured via
autodockVina.37
Screening of Subjects Affected by Syndromic
Overgrowth
We tested the DNAm signature generated for EZH2 against DNAm
profiles generated on other syndromic overgrowth cohorts
including subjects with Sotos syndrome and pathogenic variants
in NSD1 (n ¼ 49),9 Tatton-Brown Rahman syndrome and patho-
genic variants in DMNT3A (n ¼ 5),22 and susceptibility to autism
and pathogenic variants in CHD8 (n¼ 10).14 DNAmprofiles at the
229 CpG sites were extracted from each subject and tested using
the disease score correlation matrix against the DNAm profiles of
controls and WS. DNAm profiles for all these subjects were gener-
ated on the Illumina 450k array.
Cohort with Undiagnosed Overgrowth and Intellectual
Disability
Samples with undiagnosed overgrowth and intellectual disability
for whom previous testing failed to identify NSD1 and/or EZH2
coding variants were included in this analysis. These samples
were profiled on the Illumina 450k array as part of a large cohort
study of overgrowth syndromes at the Weksberg lab with samples
collected from the Division of Clinical Genetics at The Hospital
for Sick Children, at the Department of Pediatrics and Adolescent
Medicine from the University of Hong Kong, and at British
Columbia Children’s Hospital at the University of British
Columbia. TheUBC study recruited some samples referred in by in-
ternational collaborators, some of whichwere referred because of a
known variant in EZH2, and others referred in for the purposes of
identifying the cause of undiagnosed overgrowth and/or intellec-
tual disability. Samples included 73 DNAm profiles from blood-
derived DNA generated on the Illumina 450k array. DNAmprofiles
at the EZH2-specific classification signature were extracted from
each subject and tested using the disease score classificationmodel
to establish diagnosis in a search of potential individuals withWS.
Once a DNAmprofile similar toWSwas identified in these undiag-
nosed individuals, next-generation sequencing was performed on
these individuals to identify variants in PRC2 complex members.
Whole-Genome Sequencing
Subjects that were identifiedwith DNAmprofiles similar to theWS
profile were subjected to next-generation sequencing for variantrican Journal of Human Genetics 106, 596–610, May 7, 2020 599
Figure 1. Comprehensive Visualization of EZH2 Sequence Variants using ProteinPaint
Schematic representation of EZH2 sequence variants included in the study. Each distinct variant in EZH2 is represented by a disc sized in
proportion to the number of samples and filled with the color representing its class based on the legend. Missense variants which consti-
tute the large proportion of variants in EZH2 are colored in red, nonsense variants in blue, and indels in green. Sequence variants are
positioned by their amino acid coordinates based on EZH2 (GenBank: NM_004456.4, hg19). The dotted vertical lines inside the protein
delineate the boundaries of coding exons and the filled colors within the protein correspond to known protein domains.identification. About 1 mg of genomic DNA was submitted to
TCAG for genomic library preparation and whole-genome
sequencing. DNA samples were quantified using Qubit High Sensi-
tivity Assay and sample purity was checked using Nanodrop
OD260/280 ratio. 700 ng of DNAwas used as input material for li-
brary preparation using the Illumina TruSeq PCR-free DNA Library
Prep Kit following the manufacturer’s recommended protocol. In
brief, DNA was fragmented to an average size of 400 bp using son-
ication on a Covaris LE220 instrument; fragmented DNAwas end-
repaired, A-tailed, and indexed TruSeq Illumina adapters with
overhang-Ts added to the DNA. Libraries were validated on a Bio-
analyzer DNA High-Sensitivity chip to check for size and absence
of primer dimers and quantified by qPCR using the Kapa Library
Quantification Illumina/ABI Prism Kit protocol (KAPA Bio-
systems). The Validated library was paired-end sequenced on the
Illumina HiSeq X platform following Illumina’s recommended
protocol to generate paired-end reads of 150-bases in length.
Pyrosequencing
Genotyping was performed using quantitative pyrosequencing for
EZH2 variant: GenBank:NM_004456.4; c.2006G>A (p.Ser669Asn)
in a father-child pair. Targeted assay was designed using the
PyroMark Assay Design Software 2.0 (QIAGEN). Primer set se-
quences consisted of forward primer-50-AAGCTGACAGAAGAGG
GAAAGTG-30; reverse primer 50-TCCCAGCTCTGAAACATAC
CA-30 and sequencing primer 50-TTCAAGTTGAACAGAAAG-30.
The amplificationprotocolwas developedusing a biotinylated uni-
versal primer approach. Regions of interest were amplified by PCR
and pyrosequencingwas carried out using the PyroMarkQ24 pyro-
sequencer (QIAGEN) according to the manufacturer’s protocol.
Output data were analyzed using PyroMark Q24 Software
(QIAGEN),whichcalculates the allelicpercentage for eachallele, al-
lowing quantitative comparisons.
Ethics Statement
The study protocol has been approved by the Hospital for Sick
Children Research Ethics Board (REB 1000038847). All the partic-
ipants provided informed consent prior to sample collection. All600 The American Journal of Human Genetics 106, 596–610, May 7,samples and records were de-identified before any experimental
or analytical procedures. The research was conducted in accor-
dance with all relevant ethical regulations.Results
Identification of DNAm Signature in Weaver Syndrome
To identify an EZH2 DNAm signature, we generated
genome-wide DNAm profiles using Infinium Human
MethylationEPIC BeadChip arrays to test DNA from blood
samples of individuals with pathogenic sequence variants
in EZH2 and control subjects. A comprehensive map illus-
trating the specific variants in EZH2 and the number of
affected individuals for each variant is shown in Figure 1.
The complete WS cohort included 21 subjects, all of
whom had clinical features of WS and EZH2 pathogenic
sequence variants identified in molecular diagnostic labo-
ratories (Tables S1 and S2). The Canadian cohort was
used for discovery (n ¼ 8 unrelated individuals) (Table
S1) and the UK cohort was used for validation (n ¼ 8 unre-
lated subjects and n¼ 5 affectedmembers of the same fam-
ily) (Table S2). Both cohorts included individuals from in-
ternational centers. The demographics for the discovery
cohort were as follows: for WS there were five males and
three females and the mean age 5 standard deviation at
sample collection was 165 14.7 years (range 1–43 years).
The 23 sex- and age-matched control subjects included
15 males and eight females; their mean age at the time of
sample collection was 15.95 9.8 years (range 3–39 years)
(Table S3).
We used our established pipeline as outlined in the Sub-
jects and Methods for signature derivation. Of the 774,516
CpG sites tested for differential DNAm between WS-
affected case subjects and control subjects, we identified
229 statistically significant changes in DNAm across the2020
Figure 2. EZH2-Specific DNAm Signa-
ture
Principal components analysis (PCA) plot
(A) and corresponding hierarchical clus-
tering (B) (Eucledian distance metrics)
and representative heatmap of 31 samples
(n ¼ 8 WS; n ¼ 23 controls) using
the differentially methylated CpG sites
comprising the EZH2-specific DNAm
signature (229 CpG sites). In both (A)
and (B), samples labeled with red represent
Weaver syndrome, blue samples are con-
trols. On the heatmap, yellow indicates
high DNAm and blue indicates low
DNAm. For the heatmap, data are nor-
malized for visualization (mean ¼ 0,
variance ¼ 1).genome at an FDR adjusted p value < 0.05 and |Db|R 0.10
(Table S4). More than 81% of these sites showed hypome-
thylation inWS-affected case subjects compared to control
subjects and the remaining 19% displayed hypermethyla-
tion in WS. Most of these sites were mapped to gene pro-
moter regions within 5 kb of the transcription start site
(Figure S1).
The signature CpG sites were examined using principal
component analysis (PCA) (Figure 2A) and hierarchical
clustering (Figure 2B) to assess their capacity to separate
WS-affected case subjects from control subjects. As seen
in Figure 2, the significant CpGs could be used to segregate
the discovery cohort of WS-affected case subjects from
control subjects. Consistent with the analysis of DNAm
at single CpG sites, regional DNAm analysis using a bum-
phunting approach29 identified several genomic segments
that spanned between 5 and 35 CpG sites overlapping
important, previously reported targets of EZH238 (Table
S5). One example of such a genomic segment is the
HOXA gene cluster, which was also identified as significant
at the level of single CpG analysis.
Validation of the EZH2 DNAm Signature
To test the specificity and sensitivity of the EZH2 DNAm
signature, comprised of 229 CpG sites, we generated
median-methylation profiles of control subjects and WS-
affected case subjects from the discovery cohort, and clas-
sified our independent validation cohort ofWS-affected in-
dividuals (n ¼ 8) and control subjects (n ¼ 148) as either
‘‘WS’’ (positive disease score) or ‘‘not-WS’’ (negative disease
score) based on their DNAm profiles using the correlation-
based classification model (see Subjects and Methods). All
controls showed DNAm profiles similar to the control pro-
file, had negative disease scores, and were classified as ‘‘not-
WS’’ demonstrating 100% specificity (Figure 3A). Each caseThe American Journal of Humanin the WS validation cohort clustered
with WS-affected case subjects and
not with control subjects and gener-
ated positive disease scores. There-
fore, the validation cohort demon-strated 100% sensitivity (Figure 3A, Table S6). We also
tested the ability of the EZH2 signature to classify DNAm
profiles generated from a three-generation family with a
segregating EZH2 variant: GenBank: NM_004456.4;
c.466A>G (p.Lys156Glu). All affected family members
clustered with the WS-affected individuals and had posi-
tive disease scores (Figure 3A, Table S6).
To further assess the specificity of the EZH2 signature, we
evaluated its performance using a collection of control
blood DNAm data extracted from the GEO repository. As
there are very limited control data available for the EPIC
array, we utilized data from Illumina 450k arrays (n ¼
718) (Table S7) as well as control 450k array data from
our group (n ¼ 80) to compare to a subset of the WS-dis-
covery cohort also generated on the 450k array. For this
analysis, we defined 161 CpG sites that overlapped the
EZH2 signature on the EPIC and 450k arrays and used
the correlation-based classification model (see Subjects
andMethods). As seen in Figure 3B, all 798 control samples
had low disease scores for EZH2 (Table S8), so they were
predicted as ‘‘not-WS’’ (i.e., not to have pathogenic vari-
ants in EZH2), again demonstrating 100% specificity of
the signature (Figure 3B). These results highlight the
robustness of the EZH2 signature, as it overcame many
sources of variation such as sex, age, batch, and DNA pro-
cessing methods contained in the GEO cohorts.
Classifying Models for EZH2 Sequence Variants
Using the highly specific and sensitive EZH2 signature, we
tested 19 independent subjects with EZH2 sequence vari-
ants (see Table S9) using the correlation-based model for
variant classification (Table S6, Figure 4A). We found that
ten subjects had positive disease scores and were therefore
classified as ‘‘WS’’ and nine had negative disease scores and
were classified as ‘‘not-WS.’’Genetics 106, 596–610, May 7, 2020 601
A B Figure 3. Testing the Sensitivity and
Specificity of the EZH2-Specific Signature
(A) Plot representing the median-methyl-
ation profiles of WS-affected individuals
(y axis) and control subjects (x axis) using
the EZH2 DNAm signature. The dashed
line is set to represent the decision bound-
ary for which individuals above the
dashed lines have DNAm profiles more
similar to EZH2 signature and below the
dashed line have DNAm profiles more
similar to control subjects. A set of inde-
pendent WS-affected individuals (valida-
tion cohort, purple circles, n ¼ 8) as well
as a WS-affected family (light orange cir-
cles, n ¼ 5 affected members) with EZH2 pathogenic variants were classified as ‘‘WS’’ (i.e., all individuals classified as more similar to
the EZH2 signature than control subjects) indicating high accuracy of the EZH2 DNAm signature. The specificity of EZH2 signature
was estimated on an independent control validation set of 148 control samples (green crossed boxes); all subjects classified as more
similar to control subjects (specificity 100%).
(B) Performance of the EZH2 signature on data generated on 450k array including overlapping WS-affected subjects from the discovery
cohort n¼ 7 (red circles), controls n¼ 80 (blue squares), and GEO controls n¼ 718 (brown squares) generated on 450k array. All control
subjects had DNAm profiles more similar to the control profile and were therefore classified as ‘‘not-WS.’’
WS, Weaver syndrome.Next, we tested the support vector machine-learning
model (SVM), trained on significant CpG sites from the dis-
covery cohorts, on the validation sets of WS-affected case
subjects and control subjects. This model generated scores
between 0% and 100%, with high scores classified as ‘‘WS’’
and low scores classified as ‘‘not-WS.’’ We found that it
correctly predicted the classification of all WS-affected
case subjects and control samples with 100% accuracy
(Table S10). Then, we used the SVM model on the test
cohort of 19 subjects with EZH2 variants (Table S9,
Figure 4B). Ten out of the 19 variants were classified as
pathogenic or ‘‘WS’’ (scores between 70%–95%) and eight
variants were classified as benign or ‘‘not-WS’’ (scores be-
tween 0%–17%). One subject (described below) had an in-
termediate SVM score of 49%.
The correlation and SVM models were concordant for
predicting the pathogenicity of EZH2 variants in this
testing cohort (Figures 4A and 4B) with one exception.
Both models classified ten of the test cohort samples as
pathogenic and eight as benign. Those classified as patho-
genic included eight with missense variants in EZH2
(Figure 4, Table S9); five of these were de-identified samples
from PreventionGenetics, each with an associated clinical
diagnosis of WS (PG-55, PG-61, PG-75, PG-87, and PG-45).
The other three missense variants included a clinically
affected father-child pair (EX0079 and EX0080, respec-
tively) and one individual (MDL#76455) with an EZH2
variant: GenBank: NM_004456.4; c.2006G>A (p.Ser669-
Asn) inherited from a tall but clinically unaffected father
(MDL#67485). The other two variants predicted to be
pathogenic were copy number variants (CNVs) including
a previously published EZH2 deletion GenBank: NM_
004456.4; EZH2 (partial [exon20] deletion) (25.42 kb dele-
tion involving EZH2 and CUL1) associated with WS6 and
an EZH2 duplication: GenBank: NM_004456.4; c.2196-2_
2211dupAGATACAGCCAGGCTGAT.1 The latter CNV
was identified in an individual diagnosed with WS at birth602 The American Journal of Human Genetics 106, 596–610, May 7,(S126694). Although this sample had a positive disease
score, it did not cluster with the majority of WS samples.
Review of the clinical findings for this individual revealed
an atypical presentation, i.e., more severe ID than most in-
dividuals with WS, as well as seizures and contractures,
suggesting the possibility of a dual or more complex ge-
netic diagnosis.
The sample for which discordant results were obtained
was MDL#67485, the father of MDL#76455. Both father
and son were identified to have the same EZH2 variant;
however, the child had a clinical diagnosis of WS while
the father presented with tall stature but no other features
ofWS. The affected son (MDL#76455) had an SVM score of
82% and a positive disease score of 0.04 using the correla-
tion-based model. The SVM score in the father was in the
intermediate range (49%) but he had a negative disease
score of 0.12. Considering the discordant predictions
for the same variant, we investigated the possibility of so-
matic mosaicism for the EZH2 variant in the father’s
blood-derived genomic DNA. Using quantitative pyrose-
quencing, we genotyped the EZH2 variant in both the fa-
ther and the affected child and found that the percentage
of the variant allele was 46% in the blood of the child, but
only 38% in the blood of the father, suggesting somatic
mosaicism.
The eight samples that were classified by both models as
benign included five subjects with undiagnosed OGID
who inherited an EZH2 variant: GenBank: NM_004456.4;
c.553G>C (p.Asp185His). None of these individuals had
the typical features of WS. Limited family history informa-
tion was available; in one case the variant was known to be
inherited from a phenotypically normal parent (Table S9).
Two subjects with EZH2 de novo missense variants and
clinical findings atypical for WS were classified as benign
using both classification models (Figures 4A and 4B). The
subject with the EZH2 variant GenBank: NM_004456.4;
c.897þ5G>A had a height SD þ2.0, head circumference,2020
A B Figure 4. Testing the Ability of the EZH2-
Specific Signature to Classify EZH2 Vari-
ants
(A) Plot representing the median-methyl-
ation profiles of WS-affected (y axis) and
control subjects (x axis) using the EZH2
DNAm signature. A set of independent in-
dividuals with EZH2 sequence variants
(pink squares, n ¼ 19) were classified using
the EZH2 signature. Of the 19 variants, ten
classified as more similar to the EZH2
DNAm profile than controls. The remain-
ing nine variants classified as more similar
to the control profile.
(B) Plot representing the Support Vector machine (SVM) scores (y axis). The SVM prediction model was used to predict pathogenicity of
EZH2 variants based on the DNAm signature. All ten variants predicted as pathogenic in (A) had also very high SVM scores > 70% and
the remaining nine variants had very low SVM scores< 20% except one variant with an SVM score of 49%. Blue arrow represents sample
MDL#67845 (p.Ser669Asn). Orange arrow represents sample S126694 (EZH2_c.2196-2_2211dupAGATACAGCCAGGCTGAT). Green
arrow represents sample A1646 (p.Ala738Thr).
WS, Weaver syndrome.OFC SDþ1.5 (age of assessment, 6 years), andmoderate in-
tellectual disability with autism spectrum disorder (ASD).
This variant had a negative correlation-based disease
score (0.3) and low SVM score of 1% and was therefore
classified as benign or ‘‘not-WS.’’ The individual with
EZH2 variant GenBank: NM_004456.4; c.1072C>T
(p.Arg358Cys) was 6’3’’ at 21 years of age with normal
intellect. This variant had a negative disease score of
0.16 and an SVM score of 17% and was classified as
‘‘not-WS.’’
Next, we tested an interesting de novo EZH2 variant iden-
tified in an individual who presented with a phenotype
characterized by growth failure. This child was born by Ce-
sarean section at 39 weeks gestation for fetal distress. Birth
weight was 2,055 g, length 43 cm, and head circumference
33 cm. There was no family history of WS. She had tran-
sient neonatal hypoglycemia and hypotonia. At 9 months
of age she had a ‘‘clover-leaf’’ shaped skull, large anterior
fontanelle, sparse eyebrows, upslanting palpebral fissures,
and small ears. Development was moderately to severely
delayed. By age 6 years, her weight was 9 kg, length
90 cm, and head circumference < 3rd centile for age.
The EZH2 variant GenBank: NM_004456.4; c.2212G>A
(p.Ala738Thr) in this subject (A1646) was predicted to be
‘‘not-WS’’ with an SVM score of 0% and a negative disease
score of0.47. Unsupervised hierarchical clustering of this
variant showed that it clustered separately from both con-
trol subjects and from WS-affected individuals but, inter-
estingly, it generated a DNAm profile opposite to that of
the WS-affected individuals and very different from con-
trol individuals (Figures 5A and S2). This suggested that
p.Ala738Thr is a GoF variant rather than a LoF variant
for EZH2, which is also consistent with the phenotypic
presentation (undergrowth rather than overgrowth). To
further assess the putative GoF effect of this variant, a lumi-
nescence enzymatic assay was done at BPS Bioscience to
test the enzymatic activity of EZH2 p.Ala738Thr. As shown
in Figure 5B, this assay demonstrated increased enzymatic
activity of this variant compared to wild-type EZH2.The AmeNext, we performed a de novo modeling of the post-SET
domain of EZH2, building a protein structure including
the Ala738 residue and associated proteins. We used the
S-adenosyl methionine (SAM) and S-adenosyl homocyste-
ine (SAH) structures to obtain the EZH2-SAM and EZH2-
SAH complexes, respectively (Figure S3A). We found that
the substitution of the Ala738 residue to Thr does not
significantly change the affinity for SAM (Figure S3B)
whereas the substitution of the Ala738 residue to Thr in-
duces an intermediate SAM/SAH binding mode featuring
both the rotation of Gln735 side chain into a SAM-favor-
able state and a hydrogen-bond network that involves
the side chains of Gln735, p.Ala738Thr, and Tyr663, lead-
ing to an increased affinity for both cofactors (Figure S3C).
Taken together, these data support the hypothesis that this
mutant form of EZH2 has a higher affinity for an active in-
termediate state of the enzyme, leading to the observed
increased processivity (i.e., GoF).
Shared Functionality in PRC2 Complex Genes
Pathogenic sequence variants in EZH2, SUZ12, and EED,
the core components of the PRC2 complex, have been
associated with three clinically overlapping but distinct
syndromes: Weaver, SUZ12-related overgrowth, and Co-
hen-Gibson syndromes, respectively. Therefore, we tested
the ability of the EZH2 signature to predict the pathoge-
nicity of variants in EED (n ¼ 3) and SUZ12 (n ¼ 4), in in-
dividuals with features that overlap WS and also in an
individual who underwent genome sequencing for investi-
gation of ASD (no other clinical information available),
who was identified to have a 1.4 Mb 17q11.2 dup
including NF1 (MIM: 613113), SUZ12, and several RefSeq
genes (Table S9). We used both the correlation-based and
SVM models to classify these variants. All three subjects
with EED missense variants showed high SVM scores, be-
tween 92% and 96%, and had positive disease scores
(Figure 6, Tables S6 and S10), suggesting a pathogenic
variant. Two subjects with SUZ12 missense variants
(A1765 and EX0066) had high SVM scores (92% andrican Journal of Human Genetics 106, 596–610, May 7, 2020 603
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Figure 5. Gain-of-Function Variant in EZH2 Have Opposite DNA Methylation Profile at the EZH2 Signature
(A) Heatmap showing the hierarchical clustering of the DNAm profile of WS individuals (n¼ 8, red) with LoF (hypomorphic) variants in
EZH2, controls (n ¼ 23, blue) and EZH2 GoF variant (p.Ala738Thr; pink) using the EZH2 signature. On the heatmap, yellow indicates
high DNAm and blue indicates low DNAm. The subject with an EZH2 variant in pink display opposite DNAm profile when compared to
WS DNAm profiles. For the heatmap, data are normalized for visualization (mean ¼ 0, variance ¼ 1).
(B) Enzymatic activity of EZH2 GoF variant using an in vitro luminescence assay. Mutant EZH2 (p.Ala738Thr) pre-assembled into PRC2
showed increased EZH2-mediated H3K27 methylation activity.
WS, Weaver syndrome; GoF, gain of function; LoF, loss of function.96%) and positive disease scores. The third subject
(EX0067) is the father of EX0066, who presented with
mild clinical OGID features including tall stature, promi-
nent forehead, chin crease, and normal intellect, and was
identified to be mosaic for the variant by PCR based deep
sequencing. He was found to have 8.4% mosaicism in
blood leukocytes and 27% mosaicism in hair.6 While the
child had a 96% SVM score and a disease score of þ0.36,
the father had an SVM score of 19% and a disease score
of0.17. The low level of variantmosaicism in blood likely
accounts for the negative scores and for the benign classi-
fication of this variant in the father. The fourth subject
(M/R728468(2)) with a SUZ12 variant of uncertain signifi-
cance (VUS) had an SVM score of 5% and a disease score of
0.35. He presented with an atypical phenotype and in-
herited the variant from a clinically normal father,
validating its benign classification. The fifth subject
(EX0209) who harbored a duplication including SUZ12
had an SVM score of 2% and a negative disease score of
0.27, suggesting that the duplication of SUZ12 is unre-
lated to the OGID phenotype associated with LoF in
SUZ12-related overgrowth syndrome.
Classification of Overgrowth Syndromes
Since overgrowth syndromes caused by heterozygous
sequence variants in epigenes often share overlapping
clinical features, we investigated the DNAm profile gener-
ated on the 450k arrays for Sotos syndrome (n ¼ 49
[MIM: 117550]), Tatton-Brown Rahman syndrome (n ¼ 5
[MIM: 615879]), and susceptibility to ASD (n ¼ 10 [MIM:604 The American Journal of Human Genetics 106, 596–610, May 7,615032]) caused by pathogenic variants in NSD1
(MIM: 606681), DNMT3A (MIM: 602769), and CHD8
(MIM: 610528), respectively.9,14,22 The DNAm profiles of
these individuals were compared to 7 WS-affected individ-
uals (with pathogenic EZH2 variants) from the discovery
cohort and 80 control samples generated on the 450k.
All individuals with pathogenic variants in NSD1,
DNMT3A, and CHD8 received a strongly negative disease
score (Figure 7 and Table S11) and were therefore classified
as ‘‘not WS.’’
Classification of Undiagnosed Overgrowth Syndromes
In order to investigate the potential utility of the EZH2
signature as a first-tier diagnostic assay, we compared the
profiles of 73 methylomes generated in our laboratory us-
ing the 450k on blood samples from individuals with
OGID that tested negative for targeted sequencing of
NSD1 and EZH2. The goal of this analysis was to determine
whether disease-specific DNAm signatures could be uti-
lized to improve the diagnostic yield in this patient popu-
lation. Using the EZH2 signature, we were able to identify
two samples that showed a positive disease score of 0.12
and 0.2 (Figure 8, Table S11). These two subjects were clin-
ically diagnosed as WS but targeted testing of EZH2 and
subsequently EED were negative for both individuals.
Since the DNAm profiles for these two subjects clustered
with WS-affected individuals, we performed next-genera-
tion sequencing analysis on a research basis and identified
in each subject a de novo frameshift variants in SUZ12:
GenBank: NM_015355.3; c.1878del (p.Phe626Leufs*7);2020
Figure 7. Classification of Subjects with Syndromic Overgrowth
using EZH2 Signature
Plot representing samples with sequence variants in epigenes asso-
ciated with other overgrowth syndromes. These included subjects
with: NSD1 pathogenic variants associated with Sotos syndrome
(n ¼ 49, GEO: GSE74432), DNMT3A pathogenic variants associ-
ated with Tatton-Brown Rahman syndrome (n ¼ 5; GEO:
GSE128801), and CHD8 pathogenic variants associated with mac-
rocephaly and susceptibility to autism (n ¼ 10; GEO: GSE113967).
These data were compared to seven WS-affected subjects from the
discovery cohort and five test individuals with pathogenic muta-
tions in EZH2 which were run on the Illumina 450k. All over-
growth syndrome individuals had DNAm profiles more similar
to control subjects and distinguishable from WS.
Figure 6. Testing the Utility of the EZH2 Signature in Classifying
Sequence Variants in Other Components of the PRC2 Complex
Using the EZH2 signature, we compared the DNAm profiles of
three subjects with EED sequence variants (yellow triangles) and
those with SUZ12 variants (green diamonds) to the DNAm profiles
of controls (blue crossed boxes) and EZH2 pathogenic variants (red
circles). All three subjects with pathogenic variants in EED had
DNAm profiles more similar to the EZH2 profile than control sub-
jects. Two subjects with SUZ12 pathogenic variants also classified
with Weaver syndrome and the three remaining SUZ12 variants
showed DNAm profiles more similar to controls.and c.1715_1716insCA (p.Leu572Phefs*11). These two
variants were validated by Sanger sequencing as recently
reported.39 The clinical findings in both individuals were
consistent with those reported in other individuals with
SUZ12-related overgrowth, which has phenotypic overlap
with WS, as recently described.39 These data provide
further evidence for the utility of DNAm profiling as a
first-tier diagnostic tool, in addition to its previously recog-
nized proficiency as a second-tier tool for VUS classifica-
tion.9,10,40Functional Enrichment of the EZH2 DNAm Signature
Gene-set enrichment analysis was performed using
g:Profiler32 on the 89 genes that overlapped the 229
CpG sites in the EZH2 DNAm signature. The results
demonstrate enrichment for genes with roles in pattern
specification processes, skeletal system development,
and regulation of morphogenesis such as Homeobox A5
(HOXA5 [MIM: 142952]), ALX homeobox 4 (ALX4
[MIM: 605420]), and SIX homeobox 2 (SIX2 [MIM:
604994]) (Figure S4A, Table S12) (Benjamini-Hochberg
corrected p value < 0.01). This enrichment in skeletal
development and organ morphogenesis pathways reflects
the known roles of the PRC2 core complex in cellular
lineage (and subsequent tissue) specification and also re-
flects some of the cardinal features of WS (i.e., tall stature,
advanced osseous maturation, neuronal migration disor-
ders, and developmental delay) (Figure S4B), thereby
further validating the utility of this signature to elucidate
the functional, biological, and molecular impact of EZH2
pathogenic variants.The AmeDiscussion
We have identified a highly sensitive and specific EZH2
DNAm signature that can be used to classify missense var-
iants in EZH2 as pathogenic or benign. Notably, this report
offers unique insights about using DNAm signatures to
classify GoF sequence variants and detect somatic mosai-
cism. Further, this signature has utility in classifying
sequence variants in two other genes, EED and SUZ12,
that encode proteins that participate with EZH2 in the
repressive PRC2 complex. Finally, we demonstrated the
first-tier diagnostic capability of this signature, based on
its ability to predict the presence of pathogenic variants
in a PRC2 complex gene (SUZ12) in two individuals with
undiagnosed OGID syndrome.
In the development of DNAm signatures, an important
consideration is the issue of cell type variation. As DNA
methylation varies markedly among all cell types,
including hematopoietic cells,41 it is important to account
for inter-individual differences in cell types of whole
blood samples when analyzing DNAm data from this tis-
sue.42 Here, we estimated the cell proportions in the dis-
covery cohort using the Houseman method28 and
included these estimates as covariates when identifying
EZH2-specific signature. This method uses DNAm mea-
sured in purified blood cells from a small number of
healthy adults to generate cell proportion estimates inrican Journal of Human Genetics 106, 596–610, May 7, 2020 605
Figure 8. Testing the Ability of the EZH2 Signature in Classifying
Undiagnosed OGID-Affected Subjects Based on Their DNAm
Profiles
OGID-affected subjects included in this analysis were previously
tested negative for targeted mutations screening in NSD1 and
EZH2. Out of the 73 subjects with OGID (brown triangles), we
identified that most had DNAm profiles similar to control subjects
(blue squares). Interestingly, we identified two subjects with
DNAm profiles more similar to the EZH2 profile than control sam-
ples. OGID, overgrowth and intellectual disability.mixed cell populations, such as whole blood. We found no
statistically significant differences in blood cell type
composition between the affected individuals and control
subjects, which aligned with reports of individuals with
EZH2-related overgrowth having typical blood cell compo-
sition (see GeneRevies in Web Resources). Future work
measuring both complete blood counts and DNAm in
the same individuals with WS is needed to confirm the ef-
ficacy of the Houseman method in this context.
PRC2 belongs to the Polycomb group (PcG) protein fam-
ily of chromatin-modifying enzymes that function as re-
pressors of gene expression.43 In mammalian cells, PRC2
is primarily targeted to the unmethylated CpG islands of
inactive developmental genes.44 PRC2 recruitment and
binding to the targeted CpG island is facilitated in part by
polycomb-like proteins (PCLs) and JARID2 which link the
PRC2 complex to genomic sites enriched in CpG dense re-
gions.44,45 In the EZH2 LoF (hypomorphic) state, we
observed a loss of DNA methylation at CpG sites enriched
in promoter regions of developmental genes, which can
lead to transcriptional changes during critical develop-
mental time points resulting in somatic overgrowth charac-
teristic ofWS. In the caseof theEZH2GoF state,weobserved
a gain of methylation at the same CpG sites which can lead
to transcriptional changes during development resulting in
growth restriction. Further work is needed to explore the
underlying transcriptional dysregulation at the gene pro-
moters overlapping the EZH2-specific signature in relevant
cell types and critical time points during development.606 The American Journal of Human Genetics 106, 596–610, May 7,Our results support the position that the DNA methyl-
ation changes observed in individuals carrying germline
EZH2 pathogenic variants represent a downstream cascade
of events at the molecular level in response to a genetic
change. These DNAmethylation changes recur across mul-
tiple generations if the genetic change is present, demon-
strating the impact of EZH2 pathogenic variants on epige-
netic programming during embryonic development.
Evidence for this hypothesis is provided by our genome-
wide DNAmfindings in a three-generation family in which
the EZH2 variant segregates from a father to his daughter
and her three sons. All family members showed the same
EZH2-specific epigenotype. This suggests that the same ep-
igenotype was re-established downstream of a dysfunc-
tional PRC2 complex in somatic tissues of each affected
family member, in each generation. We have previously
shown similar findings in a two-generation family where
one father and two affected offspring with inherited path-
ogenic NSD1 variant all share the same NSD1-specific DNA
methylation signature.9
Constitutional pathogenic variants in EZH2 are known
to causeWS;most of these aremissense variants. Thus, pre-
dicting pathogenicity of these variants can present signifi-
cant challenges, which now can be resolved using the
EZH2 signature. Such classifications are particularly useful
for individuals with clinical findings atypical for WS who
carry de novo missense variants in EZH2. The EZH2 signa-
ture, derived from constitutional pathogenic sequence var-
iants, is comprised of differentially methylated CpG sites
in WS-affected individuals relative to control subjects;
the majority (>81%) of these sites are hypomethylated in
WS-affected individuals relative to control subjects,
whereas 19% are hypermethylated. This suggests that
pathogenic EZH2 sequence variants cause a failure of pro-
moter CpG methylation at CpG sites critically important
for normal growth and development. Support for the func-
tional relevance of the DNAm signature comes from the
fact that the most enriched CpG sites and genomic regions
overlap HOX genes, which are known targets of EZH2.38 In
cancer as well, it has been shown that loss of EZH2 contrib-
utes to epigenetic-dependent overexpression of the HOX
genes.38
We show that the EZH2 signature can differentiate the
functional effects of missense variants in EZH2 using two
previously validated classification models specifically cor-
relation-based9,14,15 and machine learning.10,40,46 We pro-
pose that review of the clinical features of subjects carrying
sequence variants in disease-associated genes, such as
EZH2, combined with the application of several methods
to visualize the data in different ways as presented here,
can improve the utility of this highly sensitive and specific
functional assay for variant pathogenicity classification.
We expect that this approach will also be useful for testing
the functionality of non-coding variants in disease-associ-
ated genes. Discordant results using the two different ana-
lytic models were of interest in assessing mosaicism in a fa-
ther with a sequence variant in EZH2 who presented with2020
tall stature, normal intellect, and no other features of WS.
Pyrosequencing studies identified low-level mosaicism in
his blood which is highly relevant for accurate genetic
counseling for the family.
In an individual with an EZH2 missense variant
(GenBank: NM_004456.4; c.2212G>A [p.Ala738Thr])
who presented with growth restriction rather than an over-
growth phenotype, we considered the possibility of a GoF
variant and used three independent approaches to assess
this hypothesis. Utilizing the DNAm signature generated
using LoF sequence variants in EZH2, we identified
DNAm alterations at most CpGs observed in the EZH2
signature but found that these were ‘‘opposite in direction’’
to the DNAm changes in the EZH2 signature. Further sup-
port for a GoF role for this variant was derived from an
in vitro luminescence assay showing increased enzymatic
activity. Finally, protein modeling showed that the
p.Ala738Thr form of EZH2 shows a strong preference for
an intermediate SAM/SAH binding state, which helps to
explain both the increased processivity observed in vitro
and to corroborate the GoF inferred from the individual-
specific methylation profile and the clinical presentation.
It has been shown that methylation of H3K27 by EZH2
requires the presence of two additional proteins: EED and
SUZ12.47 Inactivation of any one of these three protein
subunits severely compromises the enzymatic activity of
PRC2 and results in the reduction of H3K27me3.48–50
Not surprisingly, individuals with EZH2, EED, and SUZ12
pathogenic variants present with overlapping phenotypes,
including generalized overgrowth, similar craniofacial fea-
tures, advanced bone maturation, macrocephaly, and vari-
able degrees of intellectual disability.51 As there are few
specific clinical features that distinguish each of these
three disorders from each other, it is difficult in many of
these individuals, for even the most astute clinician, to
define specific genomic diagnosis in a particular case.
Here we show that the pathogenic sequence variants in
these genes that confer similar phenotypes also confer a
common DNAm signature that represents the functional
effect of PRC2 perturbation during development. As
more individuals with sequence variants in EED and
SUZ12 are identified, it will become possible to assess
whether specific DNAm ‘‘sub-signatures’’ exist for LoF var-
iants in each gene. This will be of great interest to both cli-
nicians and scientists who struggle with elucidating the
boundaries between syndromes bothmolecularly and clin-
ically (lumping versus splitting of syndromes). Although
these three conditions currently carry independent names,
some would argue that they constitute a phenotypic spec-
trum that reflects their integrated molecular actions via a
shared functional complex.
We have shown that the EZH2 signature has 100% spec-
ificity, in that it does not misclassify as positive any indi-
viduals with OGID and pathogenic variants in NSD1,
DNMT3A, or CHD8. This is congruent with what we pub-
lished previously for other OGID signatures such as
NSD1.9 We have also demonstrated that a gene-specificThe AmeDNAm signature can be more broadly applicable if that
gene encodes a protein that participates in a functional
complex. This is very important for both first-tier diagnos-
tics and for gene discovery. Our work is distinct from that
reported for the BAF complex12 in which the derivation of
the signature involved many genes in the complex. In this
paper we were able to use the information that the EZH2
signature also reflected the presence of pathogenic variants
in other PRC2 complex genes to efficiently assign a defin-
itive genomic diagnosis to two individuals with features of
OGID. In both individuals, a clinical diagnosis of WS was
suspected, but targeted sequencing for EZH2 and EED
was negative. The fact that DNAm profiles were positive
prompted us to arrange next-generation sequencing for
other genes encoding proteins in the PRC2 complex, lead-
ing to the identification of pathogenic sequence variants
in SUZ12. For the many genes that encode proteins partici-
pating in functional complexes, our approach provides a
valuable paradigm for first-tier diagnostics that could also
play an important role in future novel gene discovery.
There is considerable overlap between germline/consti-
tutional sequence variants observed in WS and the ac-
quired somatic EZH2 sequence variants observed in
myeloid malignancies. Two of the sequence variants pre-
sent in our WS-affected individuals, p.Arg684Cys and
p.Tyr733*, have also been detected as somatically ac-
quired sequence variants in myeloid malignancies.52
These two sequence variants were identified constitution-
ally in seven unrelated individuals in the current series.
None of these individuals have developed malignancies,
though it is noteworthy that the oldest of these seven in-
dividuals is less than 10 years old. Given that myeloid ma-
lignancies associated with somatic EZH2 sequence vari-
ants usually present later in life, it will be important to
follow these individuals with WS who could be at
increased risk of myeloid malignancies not only in
childhood, but also over their lifetime.3 Long-term clin-
ical data for WS will be valuable for time-to-event analysis
that estimates the age-specific malignancy risk in these
individuals.
In summary, this study demonstrates that pathogenic
LoF variants in EZH2 are associated with a highly sensi-
tive and specific DNAm signature that has significant
diagnostic power to classify pathogenic versus benign var-
iants. This study also provides unique finding wherein a
DNAm signature has the ability to distinguish GoF from
LoF variants, as well as the capability to detect somatic
mosaicism of coding EZH2 variants. Notably we also
show that the EZH2 DNAm signature can positively clas-
sify pathogenic sequence variants in two other genes,
EED and SUZ12, encoding proteins in the core PRC2 com-
plex. Finally, we have demonstrated that DNAm signa-
tures for genes that encode proteins in a functional com-
plex can play an important role not only for elucidating
molecular pathophysiology and as a tool for first- and sec-
ond-tier diagnostics, but also for paradigms for new gene
discovery.rican Journal of Human Genetics 106, 596–610, May 7, 2020 607
Data Availability
Some datasets used in this study are available publicly and
maybeobtained fromgeneexpressionomnibus (GEO)using
the following accession numbers: GSE54670, GSE54399,
GSE51245, GSE89353, GSE53045, GSE40279, GSE42861,
GSE128801, GSE36064, GSE74432, GSE113967, and
GSE128801. The remaining datasets are not publicly avail-
able due to institutional ethics restrictions.Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2020.03.008.Acknowledgments
We are grateful to all the families with childhood overgrowth con-
ditionswhoparticipated in this research and to themany clinicians
who recruited them into the study. We also acknowledge the tech-
nical assistance of Youliang Lou andChunhua Zhao. Thisworkwas
supported byCanadian Institutes of Health Research (CIHR) grants
to R.W. (IGH-155182 and MOP-126054), by CIHR Project Grant
PJT-148830 to W.T.G., and by a BCCHR intramural IGAP salary
award to W.T.G. Bioinformatic analyses were supported in part by
the Canadian Centre for Computational Genomics (C3G), part of
the Genome Technology Platform (GTP), funded by Genome Can-
ada throughGenomeQuebec andOntarioGenomics (A.L.T.,M.B.),
Genome Canada through Ontario Genomics (A.L.T., S. Choufani,
M.B., and R.W.), and theOntario Brain Institute (OBI). OBI is an in-
dependent non-profit corporation, funded partially by theOntario
government. ProteinModelingwas supportedbyTelethonFounda-
tion (grantnumberGEP13105 toG.T.), theEPIGENFlagshipProject
of the Italian National Research Council (to G.T.), the European
Research Council (grant number 616441-DISEASEAVATARS to
G.T.), and Ricerca Corrente granted by the Italian Ministry of
Health (to G.T.). The opinions, results, and conclusions are those
of the authors, and no endorsement by the Ontario Brain Institute
is intended or should be inferred.Declaration of Interests
The authors declare no competing interests.
Received: December 9, 2019
Accepted: March 10, 2020











GREAT, http://great.stanford.edu/public/html/608 The American Journal of Human Genetics 106, 596–610, May 7,OMIM, https://www.omim.org/
ProteinPaint, https://proteinpaint.stjude.orgReferences
1. Tatton-Brown, K., Murray, A., Hanks, S., Douglas, J., Arm-
strong, R., Banka, S., Bird, L.M., Clericuzio, C.L., Cormier-
Daire, V., Cushing, T., et al.; Childhood Overgrowth Con-
sortium (2013). Weaver syndrome and EZH2 mutations:
Clarifying the clinical phenotype. Am. J. Med. Genet. A.
161A, 2972–2980.
2. Gibson, W.T., Hood, R.L., Zhan, S.H., Bulman, D.E., Fejes, A.P.,
Moore, R., Mungall, A.J., Eydoux, P., Babul-Hirji, R., An, J.,
et al.; FORGE Canada Consortium (2012). Mutations in
EZH2 cause Weaver syndrome. Am. J. Hum. Genet. 90,
110–118.
3. Tatton-Brown, K., Hanks, S., Ruark, E., Zachariou, A., Duarte,
Sdel.V., Ramsay, E., Snape, K., Murray, A., Perdeaux, E.R.,
Seal, S., et al.; Childhood Overgrowth Collaboration (2011).
Germline mutations in the oncogene EZH2 cause Weaver syn-
drome and increased human height. Oncotarget 2, 1127–
1133.
4. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H.,
Tempst, P., Jones, R.S., and Zhang, Y. (2002). Role of histone
H3 lysine 27 methylation in Polycomb-group silencing. Sci-
ence 298, 1039–1043.
5. Cohen, A.S., Tuysuz, B., Shen, Y., Bhalla, S.K., Jones, S.J., and
Gibson, W.T. (2015). A novel mutation in EED associated
with overgrowth. J. Hum. Genet. 60, 339–342.
6. Imagawa, E., Higashimoto, K., Sakai, Y., Numakura, C., Oka-
moto, N., Matsunaga, S., Ryo, A., Sato, Y., Sanefuji, M., Ihara,
K., et al. (2017). Mutations in genes encoding polycomb
repressive complex 2 subunits cause Weaver syndrome.
Hum. Mutat. 38, 637–648.
7. Cohen, A.S., and Gibson, W.T. (2016). EED-associated over-
growth in a second male patient. J. Hum. Genet. 61, 831–834.
8. Lui, J.C., Barnes, K.M., Dong, L., Yue, S., Graber, E., Rapaport,
R., Dauber, A., Nilsson, O., and Baron, J. (2018). Ezh2 Muta-
tions Found in theWeaver Overgrowth SyndromeCause a Par-
tial Loss of H3K27 Histone Methyltransferase Activity. J. Clin.
Endocrinol. Metab. 103, 1470–1478.
9. Choufani, S., Cytrynbaum, C., Chung, B.H., Turinsky, A.L.,
Grafodatskaya, D., Chen, Y.A., Cohen, A.S., Dupuis, L.,
Butcher, D.T., Siu, M.T., et al. (2015). NSD1 mutations
generate a genome-wide DNA methylation signature. Nat.
Commun. 6, 10207.
10. Butcher, D.T., Cytrynbaum, C., Turinsky, A.L., Siu, M.T., Inbar-
Feigenberg, M., Mendoza-Londono, R., Chitayat, D., Walker,
S., Machado, J., Caluseriu, O., et al. (2017). CHARGE and
Kabuki Syndromes: Gene-Specific DNA Methylation Signa-
tures Identify Epigenetic Mechanisms Linking These Clini-
cally Overlapping Conditions. Am. J. Hum. Genet. 100,
773–788.
11. Grafodatskaya, D., Chung, B.H., Butcher, D.T., Turinsky, A.L.,
Goodman, S.J., Choufani, S., Chen, Y.A., Lou, Y., Zhao, C., Ra-
jendram, R., et al. (2013). Multilocus loss of DNAmethylation
in individuals with mutations in the histone H3 lysine 4 de-
methylase KDM5C. BMC Med. Genomics 6, 1.
12. Aref-Eshghi, E., Bend, E.G., Hood, R.L., Schenkel, L.C., Carere,
D.A., Chakrabarti, R., Nagamani, S.C.S., Cheung, S.W., Cam-
peau, P.M., Prasad, C., et al. (2018). BAFopathies’ DNAmethyl-
ation epi-signatures demonstrate diagnostic utility and2020
functional continuum of Coffin-Siris and Nicolaides-Baraitser
syndromes. Nat. Commun. 9, 4885.
13. Aref-Eshghi, E., Rodenhiser, D.I., Schenkel, L.C., Lin, H.,
Skinner, C., Ainsworth, P., Pare´, G., Hood, R.L., Bulman,
D.E., Kernohan, K.D., et al.; Care4Rare Canada Consortium
(2018). Genomic DNA Methylation Signatures Enable Con-
current Diagnosis and Clinical Genetic Variant Classification
in Neurodevelopmental Syndromes. Am. J. Hum. Genet.
102, 156–174.
14. Siu, M.T., Butcher, D.T., Turinsky, A.L., Cytrynbaum, C., Stav-
ropoulos, D.J., Walker, S., Caluseriu, O., Carter, M., Lou, Y.,
Nicolson, R., et al. (2019). Functional DNAmethylation signa-
tures for autism spectrum disorder genomic risk loci: 16p11.2
deletions and CHD8 variants. Clin. Epigenetics 11, 103.
15. Chater-Diehl, E., Ejaz, R., Cytrynbaum, C., Siu, M.T., Turinsky,
A., Choufani, S., Goodman, S.J., Abdul-Rahman, O., Bedford,
M., Dorrani, N., et al. (2019). New insights into DNA methyl-
ation signatures: SMARCA2 variants in Nicolaides-Baraitser
syndrome. BMC Med. Genomics 12, 105.
16. Hanna, G.L., Liu, Y., Isaacs, Y.E., Ayoub, A.M., Torres, J.J.,
O’Hara, N.B., and Gehring, W.J. (2016). Withdrawn/
Depressed Behaviors and Error-Related Brain Activity in Youth
With Obsessive-Compulsive Disorder. J. Am. Acad. Child Ado-
lesc. Psychiatry 55, 906–913.e2.
17. Accomando, W.P., Wiencke, J.K., Houseman, E.A., Nelson,
H.H., and Kelsey, K.T. (2014). Quantitative reconstruction of
leukocyte subsets using DNA methylation. Genome Biol. 15,
R50.
18. Montoya-Williams, D., Quinlan, J., Clukay, C., Rodney, N.C.,
Kertes, D.A., and Mulligan, C.J. (2018). Associations between
maternal prenatal stress, methylation changes in IGF1 and
IGF2, and birth weight. J. Dev. Orig. Health Dis. 9, 215–222.
19. Friemel, C., Ammerpohl, O., Gutwein, J., Schmutzler, A.G.,
Caliebe, A., Kautza, M., von Otte, S., Siebert, R., and Bens, S.
(2014). Array-based DNA methylation profiling in male infer-
tility reveals allele-specific DNA methylation in PIWIL1 and
PIWIL2. Fertil. Steril. 101, 1097–1103.e1.
20. Barbosa, M., Joshi, R.S., Garg, P., Martin-Trujillo, A., Patel, N.,
Jadhav, B., Watson, C.T., Gibson, W., Chetnik, K., Tessereau,
C., et al. (2018). Identification of rare de novo epigenetic var-
iations in congenital disorders. Nat. Commun. 9, 2064.
21. Alisch, R.S., Barwick, B.G., Chopra, P., Myrick, L.K., Satten,
G.A., Conneely, K.N., and Warren, S.T. (2012). Age-associated
DNA methylation in pediatric populations. Genome Res. 22,
623–632.
22. Jeffries, A.R., Maroofian, R., Salter, C.G., Chioza, B.A., Cross,
H.E., Patton, M.A., Dempster, E., Temple, I.K., Mackay,
D.J.G., Rezwan, F.I., et al. (2019). Growth disrupting muta-
tions in epigenetic regulatory molecules are associated with
abnormalities of epigenetic aging. Genome Res. 29, 1057–
1066.
23. Dogan, M.V., Shields, B., Cutrona, C., Gao, L., Gibbons, F.X.,
Simons, R., Monick, M., Brody, G.H., Tan, K., Beach, S.R.,
and Philibert, R.A. (2014). The effect of smoking on DNA
methylation of peripheral blood mononuclear cells from Afri-
can American women. BMC Genomics 15, 151.
24. Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G.,
Sadda, S., Klotzle, B., Bibikova, M., Fan, J.B., Gao, Y., et al.
(2013). Genome-widemethylation profiles reveal quantitative
views of human aging rates. Mol. Cell 49, 359–367.
25. Kular, L., Liu, Y., Ruhrmann, S., Zheleznyakova, G., Marabita,
F., Gomez-Cabrero, D., James, T., Ewing, E., Linde´n, M., Go´rni-The Amekiewicz, B., et al. (2018). DNA methylation as a mediator of
HLA-DRB1*15:01 and a protective variant in multiple scle-
rosis. Nat. Commun. 9, 2397.
26. Bibikova, M., Barnes, B., Tsan, C., Ho, V., Klotzle, B., Le, J.M.,
Delano, D., Zhang, L., Schroth, G.P., Gunderson, K.L., et al.
(2011). High density DNA methylation array with single
CpG site resolution. Genomics 98, 288–295.
27. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W.,
and Smyth, G.K. (2015). limma powers differential expression
analyses for RNA-sequencing and microarray studies. Nucleic
Acids Res. 43, e47.
28. Salas, L.A., Koestler, D.C., Butler, R.A., Hansen, H.M.,
Wiencke, J.K., Kelsey, K.T., and Christensen, B.C. (2018). An
optimized library for reference-based deconvolution of
whole-blood biospecimens assayed using the Illumina
HumanMethylationEPIC BeadArray. Genome Biol. 19, 64.
29. Jaffe, A.E., Murakami, P., Lee, H., Leek, J.T., Fallin, M.D., Fein-
berg, A.P., and Irizarry, R.A. (2012). Bump hunting to identify
differentially methylated regions in epigenetic epidemiology
studies. Int. J. Epidemiol. 41, 200–209.
30. Li, D., Xie, Z., Pape, M.L., and Dye, T. (2015). An evaluation of
statistical methods for DNA methylation microarray data
analysis. BMC Bioinformatics 16, 217.
31. McLean, C.Y., Bristor, D., Hiller, M., Clarke, S.L., Schaar, B.T.,
Lowe, C.B.,Wenger, A.M., and Bejerano, G. (2010). GREAT im-
proves functional interpretation of cis-regulatory regions. Nat.
Biotechnol. 28, 495–501.
32. Reimand, J., Isserlin, R., Voisin, V., Kucera, M., Tannus-Lopes,
C., Rostamianfar, A., Wadi, L., Meyer, M., Wong, J., Xu, C.,
et al. (2019). Pathway enrichment analysis and visualization
of omics data using g:Profiler, GSEA, Cytoscape and Enrich-
mentMap. Nat. Protoc. 14, 482–517.
33. Schu¨ttelkopf, A.W., and van Aalten, D.M. (2004). PRODRG: a
tool for high-throughput crystallography of protein-ligand
complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355–
1363.
34. Webb, B., and Sali, A. (2016). Comparative Protein Structure
Modeling Using MODELLER. Curr. Protoc. Bioinformatics
54, 1–, 37.
35. Wu, H., Zeng, H., Dong, A., Li, F., He, H., Senisterra, G., Sei-
tova, A., Duan, S., Brown, P.J., Vedadi, M., et al. (2013). Struc-
ture of the catalytic domain of EZH2 reveals conformational
plasticity in cofactor and substrate binding sites and explains
oncogenic mutations. PLoS ONE 8, e83737.
36. Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis,
J.L., Dror, R.O., and Shaw, D.E. (2010). Improved side-chain
torsion potentials for the Amber ff99SB protein force field.
Proteins 78, 1950–1958.
37. Trott, O., and Olson, A.J. (2010). AutoDock Vina: improving
the speed and accuracy of docking with a new scoring func-
tion, efficient optimization, and multithreading. J. Comput.
Chem. 31, 455–461.
38. Xu, F., Liu, L., Chang, C.K., He, Q., Wu, L.Y., Zhang, Z., Shi,
W.H., Guo, J., Zhu, Y., Zhao, Y.S., et al. (2016). Genomic loss
of EZH2 leads to epigenetic modifications and overexpression
of the HOX gene clusters inmyelodysplastic syndrome. Onco-
target 7, 8119–8130.
39. Cyrus, S.S., Cohen, A.S.A., Agbahovbe, R., Avela, K., Yeung,
K.S., Chung, B.H.Y., Luk, H.M., Tkachenko, N., Choufani, S.,
Weksberg, R., et al.; C.A.U.S.E.S. Study (2019). Rare SUZ12 var-
iants commonly cause an overgrowth phenotype. Am. J. Med.
Genet. C. Semin. Med. Genet. 181, 532–547.rican Journal of Human Genetics 106, 596–610, May 7, 2020 609
40. Aref-Eshghi, E., Bend, E.G., Colaiacovo, S., Caudle, M., Chak-
rabarti, R., Napier, M., Brick, L., Brady, L., Carere, D.A., Levy,
M.A., et al. (2019). Diagnostic Utility of Genome-wide DNA
Methylation Testing in Genetically Unsolved Individuals
with Suspected Hereditary Conditions. Am. J. Hum. Genet.
104, 685–700.
41. Reinius, L.E., Acevedo, N., Joerink, M., Pershagen, G., Dahle´n,
S.E., Greco, D., So¨derha¨ll, C., Scheynius, A., and Kere, J.
(2012). Differential DNA methylation in purified human
blood cells: implications for cell lineage and studies on disease
susceptibility. PLoS ONE 7, e41361.
42. Jaffe, A.E., and Irizarry, R.A. (2014). Accounting for cellular
heterogeneity is critical in epigenome-wide association
studies. Genome Biol. 15, R31.
43. Schuettengruber, B., Bourbon, H.M., Di Croce, L., and Cavalli,
G. (2017). Genome Regulation by Polycomb and Trithorax: 70
Years and Counting. Cell 171, 34–57.
44. Li, H., Liefke, R., Jiang, J., Kurland, J.V., Tian, W., Deng, P.,
Zhang, W., He, Q., Patel, D.J., Bulyk, M.L., et al. (2017). Poly-
comb-like proteins link the PRC2 complex to CpG islands. Na-
ture 549, 287–291.
45. Youmans, D.T., Schmidt, J.C., and Cech, T.R. (2018). Live-cell
imaging reveals the dynamics of PRC2 and recruitment to
chromatin by SUZ12-associated subunits. Genes Dev. 32,
794–805.
46. Capper, D., Jones, D.T.W., Sill, M., Hovestadt, V., Schrimpf, D.,
Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D.E., et al.610 The American Journal of Human Genetics 106, 596–610, May 7,(2018). DNA methylation-based classification of central ner-
vous system tumours. Nature 555, 469–474.
47. Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cer-
vantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N.,
Jones, A.V., et al. (2011). EZH2 mutational status predicts
poor survival in myelofibrosis. Blood 118, 5227–5234.
48. Pasini, D., Bracken, A.P., Jensen, M.R., Lazzerini Denchi, E.,
and Helin, K. (2004). Suz12 is essential for mouse develop-
ment and for EZH2 histone methyltransferase activity.
EMBO J. 23, 4061–4071.
49. Faust, C., Schumacher, A., Holdener, B., and Magnuson, T.
(1995). The eedmutation disrupts anterior mesoderm produc-
tion in mice. Development 121, 273–285.
50. Shen, X., Liu, Y., Hsu, Y.J., Fujiwara, Y., Kim, J., Mao, X., Yuan,
G.C., and Orkin, S.H. (2008). EZH1 mediates methylation on
histone H3 lysine 27 and complements EZH2 in maintaining
stem cell identity and executing pluripotency. Mol. Cell 32,
491–502.
51. Imagawa, E., Albuquerque, E.V.A., Isidor, B., Mitsuhashi, S.,
Mizuguchi, T., Miyatake, S., Takata, A., Miyake, N., Boguszew-
ski, M.C.S., Boguszewski, C.L., et al. (2018). Novel SUZ12 mu-
tations in Weaver-like syndrome. Clin. Genet. 94, 461–466.
52. Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C.,
Jones, A.V., Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., et al.
(2010). Inactivating mutations of the histone methyltrans-
ferase gene EZH2 in myeloid disorders. Nat. Genet. 42,
722–726.2020
